文献速递心力衰竭与心肌病

心力衰竭与癌症的双向关联:共享病理生理、临床结局与协同管理

Bidirectional links between heart failure and cancer: shared pathophysiology, clinical outcomes and collaborative management.
PubMed 文献 · Heart · 2026-08-03

综述指出心衰与癌症存在显著双向关系:癌症患者及幸存者心衰风险升高,主要与心脏毒性全身治疗相关;心衰患者癌症发病率亦增加。共享机制包括慢性炎症、神经激素激活、氧化应激及意义未明克隆性造血。管理需多学科心脏肿瘤学方法,兼顾肿瘤疗效与心血管安全。

要点

  • 癌症患者及幸存者心衰风险显著升高,与化疗、靶向、免疫及放疗相关。
  • 心衰患者癌症发病率亦明显增加,共享年龄、可改变危险因素及病理生理机制。
  • 管理需多学科心脏肿瘤学方法,包括风险分层、早期检测和个体化管理。

核心结论

  • 心衰与癌症存在显著双向关系,每种疾病均恶化对方预后并限制治疗选择。
  • 有效管理需多学科心脏肿瘤学方法,平衡肿瘤疗效与心血管安全并明确照护目标。
  • 早期整合姑息与康复治疗可显著改善患者生活质量和结局。

研究设计与样本

  • 综述整合现有心脏肿瘤学文献,并纳入晚期转移性癌症合并心衰管理、晚期心衰治疗在癌症患者中的应用、心脏肿瘤学照护差异与临床试验代表性三个未被充分探讨的方面。

主要发现

  • 癌症患者及幸存者心衰风险显著升高,主要由心脏毒性全身治疗驱动。
  • 心衰患者癌症发病率亦明显增加。
  • 共享机制包括慢性炎症、神经激素激活、氧化应激、失调的血管生成及意义未明克隆性造血。

临床怎么用

  • 采用多学科心脏肿瘤学方法,进行严格风险分层、系列心脏生物标志物和影像学早期检测及个体化管理。
  • 平衡肿瘤疗效与心血管安全,明确照护目标,早期整合姑息与康复治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heart failure (HF) and cancer are leading causes of global morbidity and mortality that share a significant bidirectional relationship. Epidemiologic studies reveal that cancer patients and survivors face a substantially elevated risk of HF, largely driven by cardiotoxic systemic therapies including chemotherapy, targeted therapy, immunotherapy and radiation therapy. Conversely, individuals with HF have a markedly increased incidence of cancer. This interconnection is underpinned by age and shared modifiable risk factors, including smoking, hypertension, diabetes and obesity, as well as common pathophysiological mechanisms such as chronic inflammation, neurohormonal activation, oxidative stress and dysregulated angiogenesis. Clonal haematopoiesis of indeterminate potential has emerged as a novel biological link, promoting both maladaptive cardiac remodelling and tumourigenesis. Clinically, the coexistence of HF and cancer creates complex management challenges, as each condition worsens the prognosis of the other and limits therapeutic options. In addition to providing a broad overview of the topic, this review incorporates three aspects that are underexplored in existing cardio-oncology literature-management of advanced metastatic cancer in patients with HF, use of advanced HF therapies in patients with cancer and disparities in cardio-oncology care and clinical trial representation. Effective management of patients with HF and cancer requires a multidisciplinary cardio-oncology approach that incorporates rigorous risk stratification, early detection using serial cardiac biomarkers and imaging and personalised management tailored to cancer treatment. Irrespective, cancer patients with HF have a poor prognosis. It is necessary to balance oncological efficacy with cardiovascular safety while providing a clear definition of the goals of care. Early integration of palliative and rehabilitative care can significantly improve patient quality of life and outcomes. Nevertheless, effective novel treatment strategies have significantly improved the overall survivorship for patients with cancer and/or HF.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Gill, Li, Jimenez, et al. Bidirectional links between heart failure and cancer: shared pathophysiology, clinical outcomes and collaborative management. Heart. 2026. PMID: 42571652. doi:10.1136/heartjnl-2026-328221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。